MX69
CAS No. 1005264-47-0
MX69( MX 69 | MX-69 )
Catalog No. M10044 CAS No. 1005264-47-0
A novel specific inhibitor of MDM2 inhibitor with Kd of 2.75 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 56 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 53 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 170 | In Stock |
|
| 50MG | 269 | In Stock |
|
| 100MG | 423 | In Stock |
|
| 200MG | 609 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMX69
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel specific inhibitor of MDM2 inhibitor with Kd of 2.75 uM.
-
DescriptionA novel specific inhibitor of MDM2 inhibitor with Kd of 2.75 uM; induces ubiquitination of endogenous MDM2, results in activation of p53 and inhibition of XIAP, and induces cell apoptosis and death in cancer cells; shows significant apoptotic and anti-proliferative effects on MDM2-expressing cancer cells both in vitro and in vivo, with minimal inhibitory effect on normal human hematopoiesis.
-
In VitroMX69 blocks the MDM2 protein-XIAP RNA interaction, leading to MDM2 degradation. MX69 shows minimal inhibitory effect on normal human hematopoiesis in vitro and is very well tolerated in animal models. MX69-induced MDM2 down regulation results not only in inhibition of XIAP expression, but also in activation of p53, which contributes to cancer cell apoptosis in vitro.
-
In VivoMX69-induced MDM2 downregulation results in activation of p53 which contributes to inhibition of cancer cell proliferation in vivo.
-
SynonymsMX 69 | MX-69
-
PathwayApoptosis
-
TargetMDM2-p53
-
RecptorMdm2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1005264-47-0
-
Formula Weight474.57134
-
Molecular FormulaC27H26N2O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=S(C1=CC2=C(NC(C3=CC=C(C(O)=O)C=C3)C4C2C=CC4)C=C1)(NC5=C(C)C(C)=CC=C5)=O
-
Chemical Name4-{8-[(3,4-Dimethylphenyl)sulfamoyl]-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl}benzoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gu L, et al. Cancer Cell. 2016 Oct 10;30(4):623-636.
molnova catalog
related products
-
Relugolix
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity.
-
RETRA
RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.
-
MB710
MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro.
Cart
sales@molnova.com